Emmes, a full-service clinical research organization dedicated to advancement of public health and biopharmaceutical innovation and portfolio company of Behrman Capital, has acquired Institut Dr. Schauerte.
IDS is a full-service, technology-oriented CRO specializing in late phase, non-interventional and post market clinical follow-up studies. The firm has conducted over 400 studies across a spectrum of therapeutic areas. The firm’s trial operations have been conducted in over 20 countries and has seen accelerating revenues.
This is the third acquisition made by Emmes in the 2021 following Behrman’s investment in the firm in 2019. The deal will enhance the firm’s global reach through the expansion of strategic relationships with biopharma companies.
“IDS is a highly complementary and additive business that significantly enhances the Emmes platform,” commented Grant Behrman, managing partner of Behrman Capital. “Since our initial investment, we are proud to have helped drive the Company’s rapid expansion of its global reach and customer base.”